TOVX has 36-month beta value of 0.84. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for TOVX is 8.10M, and currently, short sellers hold a 1.20% ratio of that float. The average trading volume of TOVX on June 12, 2025 was 1.34M shares.
TOVX) stock’s latest price update
Theriva Biologics Inc (AMEX: TOVX)’s stock price has gone rise by 7.07 in comparison to its previous close of 0.50, however, the company has experienced a 15.72% increase in its stock price over the last five trading days. globenewswire.com reported 2025-05-14 that – VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial –
TOVX’s Market Performance
Theriva Biologics Inc (TOVX) has seen a 15.72% rise in stock performance for the week, with a 2.42% gain in the past month and a -60.45% plunge in the past quarter. The volatility ratio for the week is 3.12%, and the volatility levels for the past 30 days are at 5.78% for TOVX. The simple moving average for the past 20 days is 9.93% for TOVX’s stock, with a -66.30% simple moving average for the past 200 days.
TOVX Trading at -41.00% from the 50-Day Moving Average
After a stumble in the market that brought TOVX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.81% of loss for the given period.
#####
#####
Stock Fundamentals for TOVX
Current profitability levels for the company are sitting at:
- -164.75 for the present operating margin
- 0.25 for the gross margin
The net margin for Theriva Biologics Inc stands at -161.12. The total capital return value is set at -1.06. Equity return is now at value -100.01, with -61.35 for asset returns.
Based on Theriva Biologics Inc (TOVX), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -12.44.
Currently, EBITDA for the company is -26.35 million with net debt to EBITDA at 0.47. When we switch over and look at the enterprise to sales, we see a ratio of -28.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.53.
Conclusion
To put it simply, Theriva Biologics Inc (TOVX) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
